TCR-based cancer immunotherapy biotech (UK)
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Louis Bacon / Moore | 55 | New buy | 197,308 | $5,948,836 | 0.1% |
| Howard Marks / Oaktree | 69 | New buy | 2,499,000 | $2,253,783 | 0.0% |
| Bridgewater | 49 | Added +90% | 18,930 | $570,740 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-06-27.